Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Leukemia immune evasion in relapse after haploidentical hematopoietic cell transplantation

Pier Edoardo Rovatti • 1 Sep 2020
EBMT 2020
Acute Myeloid Leukemia Leukemia

Pier Edoardo Rovatti, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Pier Edoardo Rovatti

CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
7:59
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
Pier Edoardo Rovatti • 1 Sep 2020
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
7:59
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
Pier Edoardo Rovatti • 1 Sep 2020

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals